Arcus Biosciences shares are trading lower. HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and announced a price target of $20.
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences shares declined after HC Wainwright & Co. initiated coverage with a Neutral rating and set a price target of $20.
October 21, 2024 | 7:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arcus Biosciences shares are trading lower following HC Wainwright & Co.'s initiation of coverage with a Neutral rating and a $20 price target.
The Neutral rating and price target of $20 by HC Wainwright & Co. suggest limited upside potential, leading to a negative short-term impact on Arcus Biosciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100